HCV epidemiology in high-risk groups and the risk of reinfection

H Midgard, A Weir, N Palmateer, VL Re III… - Journal of …, 2016 - Elsevier
Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual
practices among men who have sex with men (MSM) are important routes of hepatitis C …

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

GS Cooke, I Andrieux-Meyer, TL Applegate… - The lancet …, 2019 - thelancet.com
Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

EASL recommendations on treatment of hepatitis C 2016

European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial

GJ Dore, F Altice, AH Litwin, O Dalgard… - Annals of internal …, 2016 - acpjournals.org
Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs
(PWID). Objective: To evaluate elbasvir–grazoprevir in treating HCV infection in PWID …

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

J Grebely, O Dalgard, B Conway… - The lancet …, 2018 - thelancet.com
Background Despite revised guidelines that no longer exclude people who inject drugs
(PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to …

[HTML][HTML] KASL clinical practice guidelines: management of hepatitis C

Korean Association for the Study of the … - Clinical and …, 2016 - ncbi.nlm.nih.gov
Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework

E Day, M Hellard, C Treloar, J Bruneau… - Liver …, 2019 - Wiley Online Library
The burden of hepatitis C infection is considerable among people who inject drugs (PWID),
with an estimated prevalence of 39%, representing an estimated 6.1 million people who …

Elimination of HCV as a public health concern among people who inject drugs by 2030–What will it take to get there?

J Grebely, GJ Dore, S Morin… - African Journal of …, 2017 - journals.lww.com
Elimination of HCV as a public health concern among people w... : African Journal of
Reproduction and Gynaecological Endoscopy Elimination of HCV as a public health concern …

[HTML][HTML] Direct-acting antiviral agents for HCV infection affecting people who inject drugs

J Grebely, B Hajarizadeh, GJ Dore - Nature reviews Gastroenterology & …, 2017 - nature.com
Globally, 12 million people are estimated to have injected drugs in the past year, 50% of
whom have chronic HCV infection, with people who have previously injected drugs …

Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting

P Read, R Lothian, K Chronister, R Gilliver… - International Journal of …, 2017 - Elsevier
Abstract Background The Kirketon Road Centre (KRC) is a community-based public health
facility in Sydney, Australia, that provides healthcare to people who inject drugs (PWID) …